Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.59 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.33 |
| ▸ | CTSA | P10619 | 3/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108387 | 0.88 | METTL3 (0.46) | METTL3PPARGCHRM1GSK3B | |
| SCHEMBL1301495 | 0.88 | METTL3 (0.56) | METTL3 | |
| SCHEMBL12107926 | 0.88 | METTL3 (0.72) | METTL3THRB | |
| SCHEMBL1300242 | 0.88 | METTL3 (0.72) | METTL3THRB | |
| SCHEMBL1300623 | 0.88 | METTL3 (0.72) | METTL3THRB | |
| SCHEMBL1301499 | 0.88 | METTL3 (0.56) | METTL3 | |
| SCHEMBL12108363 | 0.86 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL12108368 | 0.86 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL13771684 | 0.86 | METTL3 (0.48) | METTL3PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL12108311 | 0.86 | METTL3 (0.58) | METTL3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2009089263-A2 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PRKAG1 1155/4885PRKAA1 1004/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PRKAG1 1155/4885PRKAA1 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.